



## Cardio-Oncology

The two top causes of death in the world are cancer and cardiovascular disease, and cardiovascular demands to the care of cancer patients are common and important given the implications for morbidity and mortality. Cancer treatment has advanced rapidly from surgery, cytotoxic chemotherapy, radiation therapy, and targeted and immune-based therapies over the past decades. These advances have led to an increase in the number of cancer survivors, however an emerging issue associated with these new cancer therapies is side effects on the cardiovascular system, which cause different spectrums of morbidity and mortality. In order to explore and detect cancer therapeutics-related cardiovascular dysfunction and mitigate its progression, the both fields are closely intertwined with each other. This Special Issue takes specific focus on the current state of cardio-oncology field and especially cancer therapy-related cardiac dysfunction — exploring the mechanisms, reviewing the current status including diagnostic and imaging modalities, team-based care and personalised approaches, and clinical unmet needs, with recommendations to minimise the risk of cardiovascular toxicity from cancer therapies and the development of dedicated cardio-oncology care.


### Guest Editors:



**Dr. Yen-Wen Wu, MD, PhD, FACC, FESC**

[wuyw0502@gmail.com](mailto:wuyw0502@gmail.com)


Division of Cardiology, Cardiovascular Medical Center, and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; National Yang Ming Chiao Tung University, School of Medicine, Faculty of Medicine, Taipei, Taiwan



**Dr. Hung-Ju Lin, MD, PhD**

[hungjulin@ntu.edu.tw](mailto:hungjulin@ntu.edu.tw)

Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University College of Medicine, Taipei, Taiwan.



**Dr. Yen-Wen Liu, MD, PhD**

[wen036030@gmail.com](mailto:wen036030@gmail.com)

Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University



**Dr. Pei-Wei Shueng, MD**

[shuengsir@gmail.com](mailto:shuengsir@gmail.com)

Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, Taiwan; National Yang Ming Chiao Tung University, School of Medicine, Faculty of Medicine, Taipei, Taiwan



## Message from the Editor-in-Chief

*Reviews in Cardiovascular Medicine* was launched in 2000 by MedReviews, LLC, in New York, NY. This journal was conceived to fill a critical gap for clinicians who were struggling with a rapidly expanding knowledge base in cardiovascular medicine with the convergence of basic science, clinical epidemiology, and therapeutic clinical trials. The founding co-editors were David P. Faxon, MD, past president of the American Heart Association, and Norman E. Lepor, MD, who is considered a luminary in interventional cardiology. The contributing editorial board grew over time and Dr. Peter A. McCullough, MD, MPH ascended from contributing, to associate, to co-editor of the Journal. In 2018, the Journal took its next big step under the leadership of Dr. McCullough as editor-in-chief to become a truly international publication. Its offices moved to IMR Press in Hong Kong, and the editorial board was made more inclusive and representative of the world-wide contributors in academic cardiology. Additionally, the journal brought on expertise in translational medicine to help face the future of molecular medicine and its role in cardiovascular disease. Today *Reviews in Cardiovascular Medicine* is considered a top tier journal in cardiology with timely and comprehensive reviews covering all aspects of cardiovascular medicine including atherosclerosis, myocardial disease, arrhythmias, and valvular heart disease. The scope of papers ranges from population science, applied basic investigation, in-vitro diagnostics, and evidence-based strategy and therapeutic trials involving both pharmacologic intervention and interventional devices. The highly integrative style of the Journal anchored with evidence tables and instructive figures has garnered many citations over the years and many guidelines documents have relied upon works published in *Reviews in Cardiovascular Medicine*. Supplement and focus issues have been very popular among the readership and often are viewed as the most up-to-date compilations of new knowledge in cardiology and related specialities. The future is bright for academic cardiovascular medicine and *Reviews in Cardiovascular Medicine* is well positioned along side the clinician-investigator in the years to come as a trusted source of critical information and analysis.

## Editor-in-chief:



**Prof. Peter A. McCullough, MD, MPH**

[peteramccullough@gmail.com](mailto:peteramccullough@gmail.com)

Texas A & M University College of Medicine, Department of Internal Medicine, Division of Cardiology, Dallas, TX

**Submission Deadline: 15 March 2022**

**Submission:** <https://jour.ipublishment.com/imr/access/login>

**Contact us:** [RCMeditorial@imrpress.org](mailto:RCMeditorial@imrpress.org)

